Researchers of the University of Basel have developed a new method with which individual isolated molecules can be studied precisely – without destroying the molecule or even influencing its quantum state. This highly sensitive technique for probing molecules is widely applicable and paves ... more
Virtual screening for active substances against the coronavirus
The University of Basel is part of the global search for a drug to fight the rampant coronavirus. Researchers in the Computational Pharmacy group have so far virtually tested almost 700 million substances, targeting a specific site on the virus – with the aim of inhibiting its multiplication. Due to the current emergency, the first results of the tests will be made available to other research groups immediately.
Over the past few weeks, the research group in the Department of Pharmaceutical Sciences, led by Professor Markus Lill, has been working with computer-aided methods to identify possible new drugs to combat the current coronavirus outbreak and similar epidemics in the future. In the process, the researchers have tested, albeit virtually, more than 680 substances on one of the virus’s key proteins: its central protease.
This “virtual screening” has already identified several interesting substances that have the potential to inhibit the virus’s critical enzyme – and thus its further multiplication. “Even if the complete development of a drug to fight this particular coronavirus is likely to exceed the duration of the current epidemic, it is important to develop drugs for future coronaviruses. This will make it possible to nip health crises like this one in the bud in the future,” says Lill.
Test results made public
In light of the current crisis, the group took an unusual decision by immediately making the test results publicly available in the form of an open-source preprint. The publication was consulted more than 3,000 times during the first 48 hours alone.
The Basel researchers hope that a larger number of research groups worldwide will test their proposals on the virus and initiate further trials. Normally, when it comes to drug design, the molecules of interest would be experimentally tested with other groups before the results were patented and published. The main focus of other ongoing coronavirus trials is currently on the usability of existing antiviral drugs or the realignment of other drugs.
- drug screening
Silicene consists of a single layer of silicon atoms. In contrast to the ultra-flat material graphene, which is made of carbon, silicene shows surface irregularities that influence its electronic properties. Now, physicists from the University of Basel have been able to precisely determine ... more
Protein variations that result from the process of alternative splicing control the identity and function of nerve cells in the brain. This allows organisms to build a highly complex neuronal network with only a limited number of genes. The study describing a detailed map of neuronal splici ... more
Zooming into a nuclear pore complex using a high-speed atomic force microscope reveals the selectivity barrier that filters the traffic of molecules passing between the cytoplasm and nucleus in eukaryotic cells. This is comprised of intrinsically disordered proteins known as FG Nucleoporins ... more
- 1A new, highly sensitive chemical sensor uses protein nanowires
- 2Diagnostic biosensor quickly detects SARS-CoV-2 from nasopharyngeal swabs
- 3New COVID-19 test quickly and accurately detects viral RNA
- 4Researcher Develops One Minute Coronavirus Test
- 5Beta cells from stem cells: Potential for cell replacement therapy
- 6How cells recognize uninvited guests
- 7A new biosensor for the COVID-19 virus
- 8The Higgs boson and superconductivity
- 9New Form of Microscopy Developed
- 10A Glimpse into Real-Time Methanol Synthesis